AccBio 2025 : 9th International Conference on Accelerating Biopharmaceutical Development
This conference series brings together senior thought leaders from across multiple disciplines to discuss strategies, technologies and capabilities that accelerate biopharmaceutical development.
Submit Your Abstract Here: https://aiche.confex.com/aiche/AccBio25/cfp.cgi
Session Topics:
Artificial Intelligence (AI) and Digital Tools for Accelerating Biopharmaceutical Process Development and Manufacturing
We will focus on the application of AI tools and machine learning to speed up end to end process development and optimizing biomanufacturing. Case studies and insights on use of Insilico first approach in discovery, process, analytical, formulation & device development, and biomanufacturing are sought.
Business Case for Sustainability
We expect case studies/examples of sustainability efforts, including technologies and productivity improvements made by companies to reduce carbon footprint in process development, device development, biomanufacturing and packaging. Our hope is that there will be an intersection between technologies like continuous manufacturing and sustainability efforts that will stimulate great discussion.
Formulation, Drug Product, and Drug Delivery
Efforts to accelerate development in the formulation, DP, and devices area would be a good discussion topic to benchmark. Challenges for new modalities could also be included. Topics that cover continuous manufacturing in these areas are also requested for discussion.
Conference Chairs
Rubi Burlage, Merck
Raghu Shivappa, Takeda
Organizing Committee
Dana Andersen, Denali Therapeutics
Hanne Bak, Regeneron
Katy Barglow, 4D Molecular Therapeutics
Glen Bolton, Amgen
Tim Charlebois, University of Delaware
Charles Cooney, Massachusetts Institute of Technology
Rohini Deshpande, Amgen
Chetan Goudar, Amgen
Aine Hanly, Vir Biotechnology
Brendan Hughes, BMS
Brian Kelley, Vir Biotechnology
Kelvin Lee, University of Delaware
J. Christopher Love, Massachusetts Institute of Technology
Greg Naugle, GSK
Gregg Nyberg, Landmark Bio
Stefanie Pluschkell, In Scope Coaching and Consulting
Arup Roy, Eli Lilly
Cleo Salisbury, Genentech
Jeff Salm, Pfizer
Gene Schaefer, University of Delaware
Ganesh Vedantham, Biomarin
Conference Organized by the Society for Biological Engineering
About SBE
Established in 2004, the Society for Biological Engineering is a technological community for engineers and applied scientists integrating biology with engineering. Members of SBE come from a broad spectrum of industries and disciplines and share in SBE’s mission of realizing the benefits of bioprocessing, biomedical and biomolecular applications. Learn more about SBE at https://www.aiche.org/sbe
Submit Your Abstract Here: https://aiche.confex.com/aiche/AccBio25/cfp.cgi
Session Topics:
Artificial Intelligence (AI) and Digital Tools for Accelerating Biopharmaceutical Process Development and Manufacturing
We will focus on the application of AI tools and machine learning to speed up end to end process development and optimizing biomanufacturing. Case studies and insights on use of Insilico first approach in discovery, process, analytical, formulation & device development, and biomanufacturing are sought.
Business Case for Sustainability
We expect case studies/examples of sustainability efforts, including technologies and productivity improvements made by companies to reduce carbon footprint in process development, device development, biomanufacturing and packaging. Our hope is that there will be an intersection between technologies like continuous manufacturing and sustainability efforts that will stimulate great discussion.
Formulation, Drug Product, and Drug Delivery
Efforts to accelerate development in the formulation, DP, and devices area would be a good discussion topic to benchmark. Challenges for new modalities could also be included. Topics that cover continuous manufacturing in these areas are also requested for discussion.
Conference Chairs
Rubi Burlage, Merck
Raghu Shivappa, Takeda
Organizing Committee
Dana Andersen, Denali Therapeutics
Hanne Bak, Regeneron
Katy Barglow, 4D Molecular Therapeutics
Glen Bolton, Amgen
Tim Charlebois, University of Delaware
Charles Cooney, Massachusetts Institute of Technology
Rohini Deshpande, Amgen
Chetan Goudar, Amgen
Aine Hanly, Vir Biotechnology
Brendan Hughes, BMS
Brian Kelley, Vir Biotechnology
Kelvin Lee, University of Delaware
J. Christopher Love, Massachusetts Institute of Technology
Greg Naugle, GSK
Gregg Nyberg, Landmark Bio
Stefanie Pluschkell, In Scope Coaching and Consulting
Arup Roy, Eli Lilly
Cleo Salisbury, Genentech
Jeff Salm, Pfizer
Gene Schaefer, University of Delaware
Ganesh Vedantham, Biomarin
Conference Organized by the Society for Biological Engineering
About SBE
Established in 2004, the Society for Biological Engineering is a technological community for engineers and applied scientists integrating biology with engineering. Members of SBE come from a broad spectrum of industries and disciplines and share in SBE’s mission of realizing the benefits of bioprocessing, biomedical and biomolecular applications. Learn more about SBE at https://www.aiche.org/sbe